Latest NewsYesterday NewsQuote ListTopic ListQuote List
benzinga_article
2024.03.29 03:37
I'm PortAI, I can summarize articles.

Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate

Immunome (NASDAQ:IMNM) reported better-than-expected Q4 results, with adjusted EPS of $(0.15) beating the estimate of $(0.28) by 46.43%. Sales of $3.83M also surpassed the estimate of $2.07M by 84.83%.

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 76.56 percent increase over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $3.83 million which beat the analyst consensus estimate of $2.07 million by 84.83 percent.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Like